Bristol-Myers Squibb(US:BMY) Yahoo Finance·2026-01-12 13:58Core Insights - Bristol-Myers Squibb Company (BMY) has a market capitalization of $113.7 billion and focuses on innovative medicines across various therapeutic areas including oncology and immunology [1] Financial Performance - BMY is expected to report an adjusted EPS of $1.65 for fiscal Q4 2025, reflecting a 1.2% decrease from $1.67 in the same quarter last year, although it has consistently exceeded Wall Street's estimates in the past four quarters [2] - For fiscal 2025, analysts project an adjusted EPS of $6.53, representing a significant increase of 467.8% from $1.15 in fiscal 2024 [3] - The company reported a stronger-than-expected Q3 2025 adjusted EPS of $1.63 and a revenue increase of 3% to $12.2 billion, with a notable 18% growth in its Growth Portfolio revenue to $6.9 billion [5] Stock Performance - BMY stock has declined by 1.7% over the past 52 weeks, underperforming the S&P 500 Index, which gained 17.7%, and the State Street Health Care Select Sector SPDR ETF, which rose by 12% during the same period [4] - Following the Q3 2025 results, BMY shares increased by 7.1% on October 30 [5] Analyst Ratings - The consensus rating for BMY stock is "Moderate Buy," with 29 analysts providing coverage, including nine "Strong Buys," one "Moderate Buy," 18 "Holds," and one "Strong Sell" [6] - BMY is currently trading above the average analyst price target of $56.17 [6]